Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 3099Neoplasms 2443Carcinoma, Non-Small-Cell Lung 1867Prostatic Neoplasms 1619Colorectal Neoplasms 1426Lung Neoplasms 1295Multiple Myeloma 929Neoplasm Metastasis 920Leukemia, Myeloid, Acute 874Pancreatic Neoplasms 848Ovarian Neoplasms 799Melanoma 784Carcinoma, Hepatocellular 737Stomach Neoplasms 639Brain Neoplasms 636Recurrence 633Squamous Cell Carcinoma of Head and Neck 632Head and Neck Neoplasms 609Glioblastoma 567Lymphoma 540Uterine Cervical Neoplasms 539Triple Negative Breast Neoplasms 505Precursor Cell Lymphoblastic Leukemia-Lymphoma 499Carcinoma, Renal Cell 499Hematologic Neoplasms 463Urinary Bladder Neoplasms 459Endometrial Neoplasms 459Colonic Neoplasms 442Lymphoma, Non-Hodgkin 436Sarcoma 434

Interventions

enzalutamide 1abiraterone 1Prednisone 1Goserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castrate Sensitive Prostate Cancer × 1 year × Clear all
NCT03860987 2026-05-22

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled
Genitourinary

Castrate Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡